Ahmed Elmahy

Dr. Ahmed Elmahy


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in NEJM AI
Verified
Journal Article
Closed access
GDGillian Doe
Gillian Doe
WBWinston Banya
Winston Banya
GEGeorge Edwards
George Edwards
MTMarko Topalovic
Marko Topalovic
EEEthaar El-Emir
Ethaar El-Emir
WMWilliam D.-C. Man
William D.-C. Man

14 September 2024 in European Respiratory Journal
Verified
Conference Paper
Closed access
HHHelene Huts
Helene Huts
KVKenneth Verstraete
Kenneth Verstraete
MSMichaël Staes
Michaël Staes
AEAhmed Elmahy
Ahmed Elmahy
WJWim Janssens
Wim Janssens
MVMaarten De Vos
Maarten De Vos
Aim: We aimed to develop a machine learning model, trained for time to first COPD exacerbation, to estimate individual treatment response to fluticasone furoate (FF) in addition to umeclidinium/vilanterol (U/V) in the IMPACT trial (NCT02164513), and compared this with a previous model for exacerbation rate. Methods: Patients in the FF/U/V (n=3989) and U/V (n=2001) arms were split (70:30) in a train (n=4193) and independent test set (n=1797). Using baseline characteristics, a t-learner of two random survival forests (one for each arm) was trained to predict changes in survival probability in response to added FF. We previously used the same train and test set to predict changes in exacerbation rate (Verstraete, K. et al. Thorax 2023; 78:983-989). Results: The survival model (C-index FF/U/V 0.59, U/V 0.63) identified a responder subgroup in the test set: hazard ratio (HR) 0.72 (p=0.01) for the 33% predicted best responders (Q1) and non-significant HR for the other 66% of the cohort (Q2 and Q3). Previously, the rate model found rate ratio (RR) 0.60 (p<0.001) for its Q1 and non-significant RR in Q2 and Q3. Patients in Q1, Q2 and Q3 for rate and survival overlapped partially. Patients predicted to be in Q1 by both models (n=271) were older (p=0.006), had milder disease (higher FEV1, lower SGRQ scores (both p<0.001)) but presented with more previous moderate exacerbations and higher blood eosinophil counts (both p<0.001) compared to patients predicted to be Q3 (33% worst responders) by both models (n=259). Conclusion: Combining models for different outcomes may better identify absolute treatment response versus nonresponse on individual patient level.

25 December 2025 in Viruses
Verified
Journal Article
Open access
PDF file
SLStefanie Lemmens
Stefanie Lemmens
KJKevin J.H. Janssen
Kevin J.H. Janssen
TNTine Nelis
Tine Nelis
AEAhmed Elmahy
Ahmed Elmahy
NPNoella - Noella Pierlet
Noella - Noella Pierlet
DSDeborah Steensels
Deborah Steensels
The recent literature has debunked the widespread hypothesis that viruses are primarily transmitted via droplets and not beyond 1.5 m, and transmission via contact has been downplayed. Hence, an evidence-based revision of the existing isolation guidelines for respiratory viruses was needed. Therefore, a completely new protocol for respiratory virus isolation in terms of personal protective equipment and patient room air purification was evaluated. Isolation relief criteria based on Ct values in follow-up sampling were assessed. A Ct value of <28 was employed as a proxy for potential active replication and associated transmissibility. Between 25% and 50% of patients who tested positive for RSV, HRV, hMPV, or SARS-CoV-2 continued to exhibit high viral loads on day 7 post-initial diagnosis, underscoring the potential for sustained infectivity. Hence, the discontinuation of isolation measures for these patients without follow-up testing may carry a considerable risk of ongoing viral transmission. On the contrary, only 7% of patients positive for Flu and 14% for PIV had a follow-up sample on day 7 with a Ct value of less than 28. Ct values increased more rapidly in influenza, indicating faster viral clearance compared to other respiratory viruses. Based on these results, the policy of a standard 7-day isolation period without follow-up testing could be adopted for influenza-positive patients.

23 October 2025 in NEJM AI
Verified
Journal Article
Closed access
GDGillian Doe
Gillian Doe
WBWinston Banya
Winston Banya
GEGeorge Edwards
George Edwards
MTMarko Topalovic
Marko Topalovic
EEEthaar El-Emir
Ethaar El-Emir
WMWilliam D.-C. Man
William D.-C. Man